CALL/AMGEN/350/0.1/17.01.25 | Real-time BOERSE MUENCHEN 12:26:19 2024-05-23 pm EDT | ||
| 1.41 EUR | -7.84% |
|
| Current month | +200.00% | ||
| 1 month | +210.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.41 | -7.84% |
| 24-05-22 | 1.53 | 0.00% |
| 24-05-21 | 1.53 | -2.55% |
| 24-05-20 | 1.57 | +3.97% |
| 24-05-17 | 1.51 | -6.21% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 12:26 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GZ8XRX |
| ISIN | DE000GZ8XRX3 |
| Date issued | 2023-02-17 |
| Strike | 350 $ |
| Maturity | 2025-01-17 (239 Days) |
| Parity | 10 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.3 € |
|---|---|
| Lowest since issue | 0.096 € |
| Spread | 0.03 € |
| Spread % | 2.11% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4
USD
Average target price
316.1
USD
Spread / Average Target
+2.15%
- Stock Market
- Warrants
- Warrant
